P53 Isoforms As Cancer Biomarkers and Therapeutic Targets

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jul 9

PMID 35804915

Authors

Liuqun Zhao

Suparna Sanyal

Affiliations

Soon will be listed here.

Abstract

This review aims to summarize the implications of the major isoforms of the tumor suppressor protein p53 in aggressive cancer development. The current knowledge of p53 isoforms, their involvement in cell-signaling pathways, and their interactions with other cellular proteins or factors suggests the existence of an intricate molecular network that regulates their oncogenic function. Moreover, existing literature about the involvement of the p53 isoforms in various cancers leads to the proposition of therapeutic solutions by altering the cellular levels of the p53 isoforms. This review thus summarizes how the major p53 isoforms Δ40p53α/β/γ, Δ133p53α/β/γ, and Δ160p53α/β/γ might have clinical relevance in the diagnosis and effective treatments of cancer.

Citing Articles

p53: The Multifaceted Roles of Covalent Modifications in Cancer.

Grigoreva T, Romanova A, Tribulovich V, Pestov N, Oganov R, Kovaleva D Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770524 PMC: 11677429. DOI: 10.3390/ph17121682.

Decoding the general role of tRNA queuosine modification in eukaryotes.

Diaz-Rullo J, Gonzalez-Moreno L, Del Arco A, Gonzalez-Pastor J Sci Rep. 2025; 15(1):345.

PMID: 39747999 PMC: 11695743. DOI: 10.1038/s41598-024-83451-y.

Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas.

Xu D, Wang L, Zheng M Immun Inflamm Dis. 2024; 12(12):e70098.

PMID: 39688352 PMC: 11650491. DOI: 10.1002/iid3.70098.

Re-appraising the evidence for the source, regulation and function of p53-family isoforms.

Lopez I, Valdivia I, Vojtesek B, Fahraeus R, Coates P Nucleic Acids Res. 2024; 52(20):12112-12129.

PMID: 39404067 PMC: 11551734. DOI: 10.1093/nar/gkae855.

Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer.

Ikliptikawati D, Makiyama K, Hazawa M, Wong R Int J Mol Sci. 2024; 25(13).

PMID: 39000572 PMC: 11242911. DOI: 10.3390/ijms25137465.

References

Lasham A, Tsai P, Fitzgerald S, Mehta S, Knowlton N, Braithwaite A . Accessing a New Dimension in TP53 Biology: Multiplex Long Amplicon Digital PCR to Specifically Detect and Quantitate Individual Transcripts. Cancers (Basel). 2020; 12(3). PMC: 7140069. DOI: 10.3390/cancers12030769. View

Niculescu 3rd A, Chen X, Smeets M, Hengst L, Prives C, Reed S . Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998; 18(1):629-43. PMC: 121530. DOI: 10.1128/MCB.18.1.629. View

Chang J, Yang D, Chang W, Chow L, Chan W, Lin H . Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells. PLoS One. 2011; 6(6):e18643. PMC: 3111415. DOI: 10.1371/journal.pone.0018643. View

Weingarten-Gabbay S, Khan D, Liberman N, Yoffe Y, Bialik S, Das S . The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA. Oncogene. 2013; 33(5):611-8. DOI: 10.1038/onc.2012.626. View

Hernandez Borrero L, El-Deiry W . Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556. PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556. View

Olivares-Illana V, Fahraeus R . p53 isoforms gain functions. Oncogene. 2010; 29(37):5113-9. DOI: 10.1038/onc.2010.266. View

Jeong S . SR Proteins: Binders, Regulators, and Connectors of RNA. Mol Cells. 2017; 40(1):1-9. PMC: 5303883. DOI: 10.14348/molcells.2017.2319. View

Ji B, Harris B, Liu Y, Deng Y, Gradilone S, Cleary M . Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics. Int J Mol Sci. 2017; 18(1). PMC: 5297727. DOI: 10.3390/ijms18010093. View

Schott A, Apel I, Nunez G, Clarke M . Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene. 1995; 11(7):1389-94. View

10.

Hafsi H, Santos-Silva D, Courtois-Cox S, Hainaut P . Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. BMC Cancer. 2013; 13:134. PMC: 3621643. DOI: 10.1186/1471-2407-13-134. View

11.

Vieler M, Sanyal S . p53 Isoforms and Their Implications in Cancer. Cancers (Basel). 2018; 10(9). PMC: 6162399. DOI: 10.3390/cancers10090288. View

12.

Nutthasirikul N, Limpaiboon T, Leelayuwat C, Patrakitkomjorn S, Jearanaikoon P . Ratio disruption of the ∆133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int J Oncol. 2013; 42(4):1181-8. DOI: 10.3892/ijo.2013.1818. View

13.

Wen Z, Zhong Z, Darnell Jr J . Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995; 82(2):241-50. DOI: 10.1016/0092-8674(95)90311-9. View

14.

Mehta S, Morten B, Antony J, Henderson L, Lasham A, Campbell H . Regulation of the interferon-gamma (IFN-γ) pathway by p63 and Δ133p53 isoform in different breast cancer subtypes. Oncotarget. 2018; 9(49):29146-29161. PMC: 6044385. DOI: 10.18632/oncotarget.25635. View

15.

Gorgoulis V, Adams P, Alimonti A, Bennett D, Bischof O, Bishop C . Cellular Senescence: Defining a Path Forward. Cell. 2019; 179(4):813-827. DOI: 10.1016/j.cell.2019.10.005. View

16.

Halaby M, Harris B, Miskimins W, Cleary M, Yang D . Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage. Mol Cell Biol. 2015; 35(23):4006-17. PMC: 4628062. DOI: 10.1128/MCB.00365-15. View

17.

Falcicchio M, Ward J, Macip S, Doveston R . Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer. Cell Death Discov. 2020; 6(1):126. PMC: 7669891. DOI: 10.1038/s41420-020-00362-3. View

18.

Chen J, Lin J, Levine A . Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med. 1995; 1(2):142-52. PMC: 2229942. View

19.

Gong L, Gong H, Pan X, Chang C, Ou Z, Ye S . p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage. Cell Res. 2015; 25(3):351-69. PMC: 4349251. DOI: 10.1038/cr.2015.22. View

20.

Bose S, Banerjee S, Mondal A, Chakraborty U, Pumarol J, Croley C . Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy. Cells. 2020; 9(6). PMC: 7348822. DOI: 10.3390/cells9061451. View